These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 17127227)

  • 21. Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.
    Roberts JA; Kwa A; Montakantikul P; Gomersall C; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2011 Mar; 37(3):225-9. PubMed ID: 21168997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia.
    Jaruratanasirikul S; Wongpoowarak W; Kositpantawong N; Aeinlang N; Jullangkoon M
    Int J Antimicrob Agents; 2012 Nov; 40(5):434-9. PubMed ID: 22959555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endotoxemia and Gram-negative bacteremia as predictors of outcome in sepsis: a meta-analysis using ROC curves.
    Hurley JC
    J Endotoxin Res; 2003; 9(5):271-9. PubMed ID: 14577843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safe use of meropenem in a patient with a possible nonimmediate allergy to imipenem.
    Lakhal K; Lortat-Jacob B; Neukirch C; Pajot O; Wolff M
    Pharmacotherapy; 2007 Sep; 27(9):1334-8. PubMed ID: 17723087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New criteria for selecting the proper antimicrobial chemotherapy for severe sepsis and septic shock.
    Periti P; Mazzei T
    Int J Antimicrob Agents; 1999 Jul; 12(2):97-105. PubMed ID: 10418753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is it safe to use carbapenems in patients with a history of allergy to penicillin?
    Sodhi M; Axtell SS; Callahan J; Shekar R
    J Antimicrob Chemother; 2004 Dec; 54(6):1155-7. PubMed ID: 15486083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy.
    Romanelli G; Cravarezza P; Pozzi A; Franchino L; Ravizzola G; Zulli R; Donati P; Prometti P; Grassi V
    J Chemother; 2002 Dec; 14(6):609-17. PubMed ID: 12583553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
    Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A;
    J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imipenem-cilastatin. A new dimension.
    S Afr Med J; 1988 Nov; 74(9 Suppl):1-8. PubMed ID: 3187839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imipenem/cilastatin with or without glycopeptide as initial antibiotic therapy for recipients of autologous stem cell transplantation: results of a Spanish multicenter study.
    de la Rubia J; Montesinos P; Martino R; Jarque I; Rovira M; Vázquez L; López J; Batlle M; de la Cámara R; Juliá A; Lahuerta JJ; Debén G; Díaz J; García R; Sanz MA
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):512-6. PubMed ID: 19285640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
    Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS
    Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the effects of a high dose of erythropoietin-beta on early endotoxemia using a rat model.
    Eren Z; Coban J; Ekinci ID; Kaspar C; Kantarci G
    Adv Clin Exp Med; 2012; 21(3):321-9. PubMed ID: 23214195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective effects of reconstituted high-density lipoprotein in rabbit gram-negative bacteremia models.
    Hubsch AP; Casas AT; Doran JE
    J Lab Clin Med; 1995 Dec; 126(6):548-58. PubMed ID: 7490514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study.
    Fabian TC; File TM; Embil JM; Krige JE; Klein S; Rose A; Melnick D; Soto NE
    Surg Infect (Larchmt); 2005; 6(3):269-82. PubMed ID: 16201937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
    Tsai HY; Chen YH; Tang HJ; Huang CC; Liao CH; Chu FY; Chuang YC; Sheng WH; Ko WC; Hsueh PR
    Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
    Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
    Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical experiences of bacteremia caused by metallo-beta-lactamase-producing gram-negative organisms.
    Lee NY; Yan JJ; Lee HC; Liu KH; Huang ST; Ko WC
    J Microbiol Immunol Infect; 2004 Dec; 37(6):343-9. PubMed ID: 15599466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reappraisal with meta-analysis of bacteremia, endotoxemia, and mortality in gram-negative sepsis.
    Hurley JC
    J Clin Microbiol; 1995 May; 33(5):1278-82. PubMed ID: 7615741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Carbapenem restriction reduce the incidence of multidrug-resistant Acinetobacter baumannii in ventilator associated pneumonia].
    Xue XS; Wang B; Deng LJ; Kang Y
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2009 Apr; 21(4):234-6. PubMed ID: 19374793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study.
    Kiratisin P; Chongthaleong A; Tan TY; Lagamayo E; Roberts S; Garcia J; Davies T
    Int J Antimicrob Agents; 2012 Apr; 39(4):311-6. PubMed ID: 22386743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.